Projected HIV Death Toll in Sub-Saharan Africa Rises as US Aid Faces Suspension
Study predicts an additional 150,000 deaths due to cuts in HIV treatment funding by the US, driven by current policy shifts.
The potential impact of suspended US funding for HIV treatment is anticipated to lead to approximately 150,000 additional deaths in Sub-Saharan Africa over the next five years.
This projection stems from research conducted by Erasmus MC in collaboration with universities across the United States, Europe, and Africa, recently published in the journal eClinicalMedicine, part of The Lancet group.
The study employed established models for HIV mortality rates in Africa to forecast preventable deaths and new infections attributable to the absence of American assistance.
These models were grounded in comprehensive public health data from Ethiopia, Kenya, Malawi, South Africa, Tanzania, Zambia, and Zimbabwe, including insights into access to HIV care, where patients receive antiretroviral therapy essential for protecting their immune systems and preventing transmission to others.
The HIV treatment landscape in Africa has significantly relied on US support since the inception of the President's Emergency Plan For AIDS Relief (PEPFAR) by President George W. Bush in 2003, which has allocated $120 billion towards combating HIV in the continent.
This initiative is acknowledged as one of the most successful health interventions, credited with saving 25 million lives over two decades.
However, recent actions under the Trump administration led to a suspension of aid that has already affected healthcare providers and systems on the ground.
According to Jan Hontelez, the lead researcher from Erasmus MC, the damage to many patients is already viewed as irreparable.
Healthcare providers in Africa have faced layoffs, severely disrupting treatment infrastructure, which now prevents access to necessary care.
Hontelez stated that even if aid is resumed, it may take up to two years to restore healthcare services to previous levels, a critical timeframe during which the health of newly treated patients could deteriorate irreversibly, resulting in avoidable deaths.
Utilizing a scenario based on a 90-day cessation of care, the predictive model estimates an increase in fatalities in the seven studied countries ranging from 60,000 to 74,000 individuals.
Given that these countries represent half of Sub-Saharan Africa, researchers conservatively project that the death toll could rise to 150,000.
The reduction in financial assistance also threatens groundbreaking research initiatives.
Clinical trials in South Africa focused on vaccines and improved treatments for both HIV and tuberculosis are jeopardized.
Ian Sanne, a physician conducting research with the AIDS Clinical Trials Group for over two decades, reported that the budget for his work was reduced by 40% due to funding cuts ordered by the Trump administration.
He emphasized the significance of this research, which does not simply constitute developmental aid but serves global health interests as infectious diseases are not contained by borders.
Additionally, South African laboratories are facing immense strain as they lose vital research funding, risking the loss of expertise gained over years.
Specifically, Professor Penny Moore, a virologist at Wits University who has dedicated 23 years to HIV vaccine research, lamented the loss of crucial support, having never been closer to securing a preventive solution for HIV. Moore highlighted the personal stakes involved, as many of her colleagues and community members are directly affected by the ongoing health crisis.
She articulated her confusion regarding the decision to suspend funding, stressing the global relevance of South African research discoveries in the fight against HIV and related infectious diseases.
This projection stems from research conducted by Erasmus MC in collaboration with universities across the United States, Europe, and Africa, recently published in the journal eClinicalMedicine, part of The Lancet group.
The study employed established models for HIV mortality rates in Africa to forecast preventable deaths and new infections attributable to the absence of American assistance.
These models were grounded in comprehensive public health data from Ethiopia, Kenya, Malawi, South Africa, Tanzania, Zambia, and Zimbabwe, including insights into access to HIV care, where patients receive antiretroviral therapy essential for protecting their immune systems and preventing transmission to others.
The HIV treatment landscape in Africa has significantly relied on US support since the inception of the President's Emergency Plan For AIDS Relief (PEPFAR) by President George W. Bush in 2003, which has allocated $120 billion towards combating HIV in the continent.
This initiative is acknowledged as one of the most successful health interventions, credited with saving 25 million lives over two decades.
However, recent actions under the Trump administration led to a suspension of aid that has already affected healthcare providers and systems on the ground.
According to Jan Hontelez, the lead researcher from Erasmus MC, the damage to many patients is already viewed as irreparable.
Healthcare providers in Africa have faced layoffs, severely disrupting treatment infrastructure, which now prevents access to necessary care.
Hontelez stated that even if aid is resumed, it may take up to two years to restore healthcare services to previous levels, a critical timeframe during which the health of newly treated patients could deteriorate irreversibly, resulting in avoidable deaths.
Utilizing a scenario based on a 90-day cessation of care, the predictive model estimates an increase in fatalities in the seven studied countries ranging from 60,000 to 74,000 individuals.
Given that these countries represent half of Sub-Saharan Africa, researchers conservatively project that the death toll could rise to 150,000.
The reduction in financial assistance also threatens groundbreaking research initiatives.
Clinical trials in South Africa focused on vaccines and improved treatments for both HIV and tuberculosis are jeopardized.
Ian Sanne, a physician conducting research with the AIDS Clinical Trials Group for over two decades, reported that the budget for his work was reduced by 40% due to funding cuts ordered by the Trump administration.
He emphasized the significance of this research, which does not simply constitute developmental aid but serves global health interests as infectious diseases are not contained by borders.
Additionally, South African laboratories are facing immense strain as they lose vital research funding, risking the loss of expertise gained over years.
Specifically, Professor Penny Moore, a virologist at Wits University who has dedicated 23 years to HIV vaccine research, lamented the loss of crucial support, having never been closer to securing a preventive solution for HIV. Moore highlighted the personal stakes involved, as many of her colleagues and community members are directly affected by the ongoing health crisis.
She articulated her confusion regarding the decision to suspend funding, stressing the global relevance of South African research discoveries in the fight against HIV and related infectious diseases.
